Sravnitel'noe issledovanie effektivnosti otechestvennogo generika i original'nogo preparata zoledronovoy kisloty u patsientok s maloenergeticheskimi perelomami tel pozvonkov i postmenopauzal'nym osteoporozom
- Authors: Kochish A.Y.1, Ivanov S.N1
-
Affiliations:
- Issue: No 10 (2014)
- Pages: 24-29
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286996
- ID: 286996
Cite item
Abstract
A prospective comparative study in two comparable clinical groups of women with low-energy compression fractures of the vertebral bodies on the background of postmenopausal osteoporosis was performed; the study has shown comparable efficacy and safety of anti-osteoporotic pharmacotherapy with domestic generics Rezoklastin FS (5 mg/6.25 ml), and the original drug of zoledronic acid Aclasta (5 mg/100 ml). The use of Rezoklastin FS is accompanied by relatively lower incidence of influenza-like effect, a marked positive effect on bone mineral density, confirmed by the results of dual energy X-ray densitometry, as well as the ability to prevent the occurrence of repeated low-energy vertebral compression fractures at 1-year follow-up. This allows to recommend the domestic drug of zoledronic acid Rezoklastin FS as an effective medicine for the secondary prevention of repeated vertebral osteoporotic fractures in women with postmenopausal osteoporosis.
Full Text
References
- Cause-specific mortality, 2008: WHO region by country. Geneva: World Health Organization, 2011.
- Dunford J.E., Thompson K., Coxon F.P., et al. Stucture-activiti relationships forinhibition of farnesyl diphospate synthase in vitro and inhibition of bone resorption in vitro by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001; 296: 235-42.
- Евстегнеева Л.П., Лесняк О.М., Пивень А.И. Эпидемиология остеопоротических переломов позвоночника по данным рентгеноморфометрического анализа среди популяционной выборки жителей г. Екатеринбурга 50 лет и старше. Остеопороз и остеопатии. 2001: 2: 2-6.
- Brown J.P., Josse R.J. 2002 clinical practice guidelines for diagnosis and management of osteoporosis in Canada. CMAJ. 2002; 10(167. Suppl.): S1-S34.
- Продан А.И., Гоунтовский Г.Х., Попов А.И. и др. Биомеханическое обоснование оптимального состава композитного материала для чрезкожной вертебропластики. Хирургия позвоночника. 2006; 2: 68-74.
- Никитинская О.А., Торопцова Н.В. Состояние проблемы диагностики и лечения остеопороза в реальной клинической практике (пилотное исследование). Современная ревматология. 2014; 2: 47-51.
- Кочиш А.Ю., Иванов С.Н., Хрулев В.Н. Профилактика повторных компрессионных переломов тел позвонков с использованием препарата золедроновой кислоты. Травматология и ортопедия России. 2010; 2(56): 113-15.
- Okabe R., et al. Clinical evaluation of the elecsys β-CrossLaps Serum assay, new assay for degradation products I type collagen C-telopeptides. Clinical Chemistry. 2004; 47: 1410-14.
- Lyles K.W., et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N. Engl. J. Med. 2007; 357: 1799-809.